Alex Melamed

Gynecologic Oncology practice @MassGenNews. Researching how real-world cancer care affects real-world patients. He/his/him/himself

[Alex Melamed @headofmelon]

Our latest lead by Dr. Katy Abel. More evidence that underutilization of NACT is associated with worse post-operative outcomes, without any hint of long-term benefit, even in high-volume centers.

[JAMA Network Open @JAMANetworkOpen]

For patients with advanced-stage ovarian cancer, higher utilization of neoadjuvant chemotherapy at high-volume centers was associated with the lowest 90-day surgical mortality and longest 60-month survival. https://t.co/NvOIMK7ZET

[Núria Agustí Garcia @nagustiga]

Our JAMA Oncology study is now featured in the @IJGConline podcast! Thank you for highlighting our work.

Grateful to work with such an amazing team! @dviverosc @headofmelon @NiteckiRoni @RParejaGineOnco @RauhHainMD

[Alex Melamed @headofmelon]

https://t.co/bwx6SuLOLI

[Alex Melamed @headofmelon]

LANCE trial lead-in pilot shows the feasibility of a phase III study to evaluate the efficacy of MIS for interval cytoreduction in ovarian cancer. @RauhHainMD @annafagottimd @RParejaGineOnco @pedroramirezMD @abedsinno

[JAMA Network Open @JAMANetworkOpen]

LANCE RCT: A minimally invasive surgery for advanced ovarian cancer after neoadjuvant chemotherapy is feasible and may reduce postoperative complications compared to laparotomy. https://t.co/ZfEn4aamYF

[Alex Melamed @headofmelon]

What an honor for us to host @scambiagiovanni and @annafagottimd at @MghObgyn.

[Alex Melamed @headofmelon]

Cool picture of a adenosarcoma assocaited uterine inversion which we treated laparoscopically. Nice work by Baran Vardar and @AlexBercowMD getting these pictures into the literature.
https://t.co/D6Yy7Erjpp

[Alex Melamed @headofmelon]

https://t.co/pfYw7uNQmM

[Alex Melamed @headofmelon]

Josseli Barnica is the victim of a totalitarian state imposing its ideology on women’s bodies. America we are better than this.

[Alex Melamed @headofmelon]

NACT and interval cytoreductive surgery edges out primary cytoreductive surgery as the most frequent treatment for advanced-stage ovarian cancer in the US. 11 years after Vergote et al. It really does take a decade.

[JAMA Network Open @JAMANetworkOpen]

Since 2021, neoadjuvant chemotherapy followed by interval cytoreductive surgery has become the most prevalent approach of upfront treatment for patients with advanced epithelial ovarian cancer in the US. https://t.co/O7VL0HmlaF

[Alex Melamed @headofmelon]

Thanks @IJGConline and @pedroramirezMD for this great honor.

[IJGC @IJGConline]

📣 Great news!!!
Dr. Alexander Melamed joins the #IJGC #AssociateEditors team 🔥 🔥

Welcome Alex!🤩

@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4

[Alex Melamed @headofmelon]

@just_cameron @arieda_muco

[Alex Melamed @headofmelon]

@GeorgiaTomova @IntJEpidemiol Yikes

[Alex Melamed @headofmelon]

@ebonycartermd @UNC They are lucky to have you!

[Alex Melamed @headofmelon]

A new paper by super intern Katy Abel looks at the use and efficacy of primary site surgery in metastatic cancer. There is a lot of heterogeneity across cancer sites, raising essential questions about how, and if, we know when surgery is helpful

https://t.co/DRXYL9mUcp

[Alex Melamed @headofmelon]

A new paper by Jason Silberman @JSilby3: who is on the market for the gyn onc fellowship spot!

https://t.co/96GXOnqXyW

cytotoxic NACT has increased for stage III&IV low-grade serous ovarian cancer in last 15y w/o evidence that this approach is effective in this cancer type

[Alex Melamed @headofmelon]

@s_j_prins "he does not share our beliefs about the state's role in defining normative interpersonal relationships, therefore his ideas are suspect" is not a good argument.

lots of statisticians and epidemiologists who had shitty beliefs still made useful contributions.

[Alex Melamed @headofmelon]

@s_j_prins like Vanderweele's stuff or not, his beliefs re: gay marriage (as much as you and I may find them to be reprehensible) have nothing to do with the argument he and others have made about how to formalize and operationalize ideas about causation. This kind of argument is lame.